Riggs Asset Management’s Akero Therapeutics AKRO Stock Holding History

Riggs Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14	Closed	-$354	–	658
2024 Q1	$354	Buy	+14	New	+$336	﹤0.01%	588

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Riggs Asset Management's AKRO Position: Q2 2024 in Review

Riggs Asset Management sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 14 shares — an estimated $354 sold.

Riggs Asset Management first reported a position in AKRO in Q1 2024 and held it in 1 quarter. The position peaked at $354 in Q1 2024. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

Riggs Asset Management reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
Riggs Asset Management sold 14 Akero Therapeutics shares in Q2 2024, an estimated $354.
Riggs Asset Management first reported a position in Akero Therapeutics in Q1 2024 and held it in 1 quarter.
Riggs Asset Management's Akero Therapeutics position peaked at $354 in Q1 2024.
153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Riggs Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.